Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Clinical Trials
1.5k
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1395 trials with phase data)• Click on a phase to view related trials
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 218
- Registration Number
- NCT07053423
Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 350
- Registration Number
- NCT07052396
Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)
- Conditions
- Type 1 Diabetes
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3500
- Registration Number
- NCT07038473
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT07007962
Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults
- Conditions
- Yellow Fever Immunization
- Interventions
- Biological: Yellow fever vaccine (live)Biological: YF vaccine (live)
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 640
- Registration Number
- NCT07002060
- Locations
- 🇺🇸
Velocity Clinical Research-New Orleans- Site Number : 8400004, New Orleans, Louisiana, United States
🇺🇸Rochester Clinical Research- Site Number : 8400005, Rochester, New York, United States
🇺🇸Velocity Clinical Research - Providence- Site Number : 8400003, East Greenwich, Rhode Island, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 294
- Next
News
Renasant Bio Raises $54.5M to Develop Novel Ion Channel Therapies for ADPKD
Renasant Bio secured $54.5 million in seed funding from investors including 5AM Ventures, Atlas Venture, OrbiMed and Qiming Venture Partners USA to develop treatments for autosomal dominant polycystic kidney disease (ADPKD).
Sanofi Launches Long-term Safety Study for TZIELD in Stage 2 Type 1 Diabetes Patients
Sanofi has initiated an observational study to evaluate the long-term safety and efficacy of TZIELD (teplizumab-mzwv) in patients with Stage 2 Type 1 Diabetes.
EPO and UPC Reach Opposite Conclusions on Amgen's PCSK9 Antibody Patent Validity
The European Patent Office (EPO) Opposition Division upheld Amgen's PCSK9 antibody patent EP 3666797, finding it inventive, while the Unified Patent Court (UPC) Central Division revoked the same patent for lacking inventive step.
bluebird bio Strengthens Leadership Team with Three Key Executive Appointments
bluebird bio, a pioneer in gene therapies for severe genetic diseases, has appointed three new executives to strengthen its leadership team as the company focuses on commercial execution.
ESTEVE Acquires Caprelsa Rights from Sanofi to Expand Rare Cancer Treatment Portfolio
ESTEVE has entered into an agreement with Sanofi to acquire Caprelsa® (vandetanib) rights in more than 50 countries for treating aggressive and symptomatic medullary thyroid cancer in adults and children above 5 years of age.
Alzheimer's Drug Market Sees 780% Investment Surge Following Leqembi and Kisunla Approvals
Total M&A deal value in Alzheimer's disease jumped from $2 billion in 2022 to $18 billion in 2024, representing a 780% increase following the approval of disease-modifying treatments.
Vor Bio Secures Global Rights to Telitacicept in $4+ Billion Deal with RemeGen
Vor Bio acquired exclusive global rights (excluding Greater China) to develop and commercialize telitacicept, a dual-target fusion protein approved in China for multiple autoimmune diseases including generalized myasthenia gravis.
CDC's Reconstituted Vaccine Advisory Panel Votes to Eliminate Thimerosal from All Flu Vaccines
The newly appointed Advisory Committee on Immunization Practices (ACIP) voted 5-1 to recommend thimerosal-free influenza vaccines for all age groups, despite the preservative being present in only 6% of U.S. flu vaccines.
MIRA Pharmaceuticals Unveils Preclinical Data for SKNY-1, Targeting Obesity and Smoking Cessation Without CNS Side Effects
MIRA Pharmaceuticals announced new in vitro preclinical data from Eurofins demonstrating SKNY-1's potential as a first-in-class oral therapy for obesity and nicotine addiction without central nervous system side effects.
Sanofi Advances Kymera's Next-Generation IRAK4 Degrader KT-485 to Clinical Testing
Sanofi has selected Kymera's KT-485, a next-generation oral IRAK4 degrader, to advance into Phase 1 clinical testing next year for immuno-inflammatory diseases.